Latest filing published 23 Aug 2022 for Cue Biopharma, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Kerri-Ann Millar: trading record in brief
Kerri-Ann Millar (finance chief) discloses dealings in Cue Biopharma, Inc. to SEC (Form 4). Between 29 August 2018 and 22 August 2022, the trades on record add up to 9 filings.
In open-market terms, that means 1 purchase worth €7,242 on one side and 1 sale worth €15k on the other. The net balance comes to €8,117 on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 share grants and 4 option exercises.
The newest entry dates from 23 August 2022: a share grant of €8,678, in Cue Biopharma, Inc. The last insider purchase was made public on 29 August 2018, 2,994 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Kerri-Ann Millar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,667 sharesCommon StockSEC:0001209191-22-047161:0
- 6,667 shares0Common StockSEC:0001209191-21-059698:0
2 of 2 declarations
